Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitroso-dabigatran (NDAB) Impurity. March 21, 2023. Parsippany.

Roche announced today that the U.S. FDA has approved a supplemental new drug application to market Tamiflu (oseltamivir phosphate) capsules in 30 mg and 45 mg doses.